SCHEMBL25072913

SCHEMBL25072913

COC(=O)c1ccc(NS(=O)(=O)Cl)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 4/20 0.54
▸ CMA1 P23946 1/20 0.54
▸ MAPT P10636 4/20 0.53
▸ KMT2A Q03164 1/20 0.51
▸ ALDH1A1 P00352 5/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ TSHR P16473 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ HPGD P15428 4/20 0.47
▸ PYGL P06737 1/20 0.46
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ LMNA P02545 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ CA12 O43570 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ XDH P47989 1/20 0.44
▸ CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25139809 0.86 SMN1; SMN2 (0.66) CYP2C9CMA1MAPTKMT2AALDH1A1
SCHEMBL25072707 0.86 MAPT (0.54) CYP2C9CMA1MAPTKMT2AALDH1A1
SCHEMBL25072525 0.85 MAPT (0.53) CYP2C9CMA1MAPTKMT2AALDH1A1
SCHEMBL1138924 0.80 CYP2C9 (0.63) CYP2C9CMA1MAPTKMT2AALDH1A1
SCHEMBL2339935 0.79 MAPT (0.60) CYP2C9MAPTKMT2AALDH1A1KDM4E
SCHEMBL25072828 0.78 CA12 (0.59) TSHRNPSR1PYGLCA1CA2
SCHEMBL30545664 0.78 TRPV4 (0.58) CYP2C9MAPTKMT2AALDH1A1KDM4E
SCHEMBL9093802 0.78 TRPV4 (0.58) CYP2C9MAPTKMT2AALDH1A1KDM4E
SCHEMBL6972221 0.78 ALDH1A1 (0.64) CYP2C9MAPTKMT2AALDH1A1KDM4E
SCHEMBL25072992 0.78 CYP2C9 (0.64) CYP2C9CMA1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4387603-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF Enanta Pharmaceuticals, Inc. (US) 2024-06-26 — — EP disclosed
CN-118103038-A 17 Beta-hydroxysteroid dehydrogenase 13 inhibitors and methods of use thereof 英安塔制药有限公司 2024-05-28 — — CN disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 CYP2C9 226/4885CMA1 816/4885MAPT 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback